Although this prevailing model implicates the aggregation of amyloid-beta (Aβ) plaques and the formation of hyperphosphorylated tau (p-Tau) fibrils as seminal events in AD pathogenesis, pharmacological strategies targeting these entities have largely failed to yield transformative clinical outcomes [48]. Here, MAPT is linked to Alzheimer disease.